The science behind Regenerative Medicine allows the body to self-heal and repair within its natural capacity. It enhances the body’s natural process of regenerating and replacing human cells and tissues. Traditionally, diseases are commonly treated with prescription medicine, painkillers, and surgery.
To realize this noble mission with vast potential in the medical field, Cell Tissue Technology Sdn. Bhd., Malaysia’s FIRST Tissue Engineering Firm endorsed by the Malaysia Book of Records in 2016, has established the most ambitious regenerative program in the nation, coupling biology, clinical science, and engineering – RegenMed by Celllora®.
RegenMed by Celllora® aims to target diseases without causing severe adverse effects, unlike conventional treatments. Success in our mission will impact patients’ lives, bring economic benefits, serve to train the next generation of researchers, and advance the expertise of our faculty in the basic sciences, engineering, and clinical sciences.
To realize this noble mission with vast potential in the medical field, Cell Tissue Technology Sdn. Bhd., Malaysia’s FIRST Tissue Engineering Firm endorsed by the Malaysia Book of Records in 2016, has established the most ambitious regenerative program in the nation, coupling biology, clinical science, and engineering – RegenMed by Celllora®.
RegenMed by Celllora® aims to target diseases without causing severe adverse effects, unlike conventional treatments. Success in our mission will impact patients’ lives, bring economic benefits, serve to train the next generation of researchers, and advance the expertise of our faculty in the basic sciences, engineering, and clinical sciences.
CelltiX is an extracted communicating vesicles derived from Umbilical Cord Derived Mesenchymal Stem Cells (MSCs). CelltiX is prepared in our state-of-the-art cGMP facility. Celltix is a new type of major paracrine factor released by MSCs into a culture medium, playing an important function in a multitude of biological processes. |
CelltiSS is a conditioned media formulated for topical administration to wound areas; used to treat and manage wounds and major skin loss. CelltiSS consists of various types of bioactive factors secreted by fibroblasts. The conditioned media is obtained from a cell culture collected at 80-90% confluency of the culture, which is the confluency at which the cells are in a mitotic phase, and there is maximum production of bioactive factors. |
MyDerm® is an Autologous Bilayered Tissue Engineered Human Skin construct. The epidermal layer consists of 5 to 20 million keratinocytes embedded in a fibrin matrix developed by human plasma while the dermal layer consists of 5 to 20 million fibroblasts embedded in a fibrin matrix developed with human plasma. |
CELL TISSUE TECHNOLOGY SDN BHD
Malaysia's FIRST Tissue Engineering Firm |
|
